IQVIA Holdings Inc. $IQV Shares Sold by Cantillon Capital Management LLC

Cantillon Capital Management LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 11.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,710,896 shares of the medical research company’s stock after selling 230,248 shares during the quarter. IQVIA comprises about 1.9% of Cantillon Capital Management LLC’s investment portfolio, making the stock its 23rd biggest position. Cantillon Capital Management LLC’s holdings in IQVIA were worth $291,776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Boston Partners purchased a new position in IQVIA in the 3rd quarter worth approximately $676,698,000. Norges Bank bought a new stake in shares of IQVIA in the 4th quarter worth about $497,445,000. Victory Capital Management Inc. raised its stake in IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after buying an additional 1,614,063 shares in the last quarter. Orbis Allan Gray Ltd raised its position in shares of IQVIA by 96.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after acquiring an additional 933,554 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $206.26 on Monday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market capitalization of $34.42 billion, a price-to-earnings ratio of 25.56, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20. The business has a 50 day simple moving average of $185.04 and a 200 day simple moving average of $187.88.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the business earned $2.70 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities analysts have commented on IQV shares. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Robert W. Baird raised their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Mizuho upped their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.71.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.